Introduction {#S1}
============

Olfactory impairment (OI) is known to occur during the process of aging (odds ratio \[OR\] = 1.55 for every 5-year increase in age) ([@B83]). It is estimated that more than 50% of the population aged between 65 and 80 years old exhibit OI, increasing to 75% above 80 years old ([@B22]). Several hypotheses are proposed to explain this age-related decline of olfaction.

First, the olfactory nerve, originating from the nasal fossa, is the only cranial nerve directly exposed to the environment, which makes it vulnerable to exposure to toxins, infection, trauma, and airborne pollutants ([@B42], [@B43]; [@B2], [@B3]).

Second, age-related alteration of physiological processes and structural changes within the nose, olfactory epithelium, olfactory bulb and higher brain regions seem to contribute greatly to this deterioration ([@B11]; [@B22]; [@B5]; [@B35]; [@B20]; [@B63]).

Third, brain aging or environmental exposure could reduce the cellular regeneration found at the different levels of the olfactory system ([@B44]).

Fourth, genetic factors could also be involved. For example, it has been shown that carriers of val/val genotype of the brain-derived neurotrophic factor (BDNF) val66met polymorphism present a marked aging-associated decline in olfactory function ([@B38]). Apolipoprotein E (ApoE) ε4 allele carriers seem to experience greater olfactory decline than the non-carriers ([@B93]). ApoE may also contribute to neuronal regenerative processes and to the development of neurodegenerative diseases. Interestingly, the combination of ApoE ε4 allele and OI in a non-demented elderly population predicts a larger decline in global cognitive function ([@B7]; [@B70]). As for cognitively impaired individuals, ApoE ε4 allele carriers also show a more significant decline in cognitive abilities as well as in odor identification ([@B93]). However, a twin study suggests low heritability coefficients regarding olfactory function ([@B23]).

Fifth, age-related OI could reflect early involvement of olfactory-related brain areas by the neuropathological processes associated with neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD). Even if the exact mechanisms underlying OI in AD and PD are not completely understood, olfactory brain structures are affected early in their courses ([@B8]; [@B63]) and OI precedes clinical diagnosis. Regarding AD, OI may already be present in patients with mild cognitive impairment (MCI, cognitive dysfunction exceeding normal "age-related" decline, yet not meeting the criteria for dementia) ([@B81]). It is known that approximately 70% of MCI patients will ultimately convert to AD ([@B28]). Yet, recent data converge toward the idea that olfactory-impaired MCI patients are more prone to develop AD than those without OI ([@B12]; [@B17]; [@B1]; [@B47]). Overall, these findings make OI a potential early predictor for AD development. PD is also marked by early OI, which typically precedes motor symptoms by at least 5 years and thus can be used as a biomarker for the diagnosis of PD ([@B6]; [@B63]; [@B36]). Moreover, a 7-year prospective study conducted in newly diagnosed PD patients reported that hyposmia at diagnosis of PD is associated with further development of cognitive deficits, making OI a predictor of dementia in this setting ([@B30]).

Sixth, OI has been shown to accompany a variety of diseases. In addition to the link to neurodegenerative diseases, OI has been reported to occur in schizophrenia, epilepsy, systemic and endocrine diseases (e.g., hypothyroidism, type 2 diabetes mellitus), chronic kidney or liver failure ([@B51]; [@B46]; [@B42]). Of note, a recent study involving type 2 diabetic patients demonstrated not only increased OI in this population compared to controls but also diminished abilities in specific cognitive tests. Besides, once again, they found a strong association between OI and specific memory impairment in this population ([@B98]). As for smoking, which is known to interfere with olfactory performance, the effect is equivocal or weak and mostly seen in long-standing heavy smokers ([@B61]). Alcohol's abuse negative effects on olfaction could be related to alterations in brain areas involved in olfactory processing ([@B83]). Higher probability of comorbidities with age comes along with the associated polypharmacy. Despite little evidence-based data, it is commonly thought that medication may affect taste and smell functions ([@B46]). Drugs are thought to interact with many different molecular targets of the olfactory pathway from the olfactory receptors to central processes ([@B58], [@B57],[@B60]). A long list of medications might be involved in smell loss, including antibiotics, antidepressant and antipsychotic drugs, antihypertensive drugs (e.g., calcium channel blockers), opioids, sildenafil ([@B21]; [@B46]). However, it is difficult to distinguish drug-induced OI from the effect of the underlying medical issue for which the drug is taken. [@B51] did not find a correlation between olfactory function and the number of drugs taken. Nevertheless, a recent study showed a significant correlation between the number of drugs taken and both worse olfactory threshold function and, interestingly, worse MMSE scores ([@B71]). The authors justified this finding by the fact that these parameters are usually age-related. However, they did not control for comorbidities, which in fact could have explained in part these results.

Summary of Existing Studies Linking Olfactory Impairment and Mortality {#S2}
======================================================================

Until now, seven longitudinal studies have been published on the relationship between olfactory function at baseline and risk of mortality ([@B96]; [@B33]; [@B75]; [@B18]; [@B87]; [@B24]; [@B56]). Demographics and methods are summarized in [Table 1](#T1){ref-type="table"}. Statistics and main results are summarized in [Table 2](#T2){ref-type="table"}. We deliberately decided to include only studies with psychophysical assessment of olfactory function using well-known validated identification tests since self-assessment of olfactory function is not reliable ([@B52]; [@B59]; [@B69]; [@B68]). Together, these studies included a total of 13,366 individuals, male and female, aged 40 and older, with older people representing the majority. In regard to age groups, results vary between studies. Some found a stronger OI-mortality link in older subjects, while others demonstrated a slightly stronger relationship in middle-aged groups ([@B33]; [@B24]; [@B56]). This latter finding may be due to the increased prevalence of anosmia with advancing age. Length of follow-up varied according to studies, mainly ranging from 4--5 years up to 10--13 years. Exclusion criteria, mostly including dementia or neurologic diseases, were found in four studies and are discussed below.

###### 

Studies linking olfactory impairment and mortality -- Demographic data and methods.

  References   Sample size (n)   Length of follow-up                    Mean age, age range                                                      Exclusion criteria                                                                                                                                  Olfactory test
  ------------ ----------------- -------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  [@B96]       1162              Mean of 4.2 years, range: 0--9         79.7 years, no data                                                      Diagnosis of dementia or PD                                                                                                                         Brief Smell Identification Test (BSIT) (12 points score)
  [@B33]       1636              5 years                                Presence of OI: 77.2 years, no data Absence of OI: 72.1 years, no data   None                                                                                                                                                San Diego Odor Identification Test (SDOIT) (8 points score)
  [@B75]       2918              5 years                                68 years, 57--85                                                         None                                                                                                                                                Validated modified score using items from the Sniffin' Sticks identification test (5 points score)
  [@B18]       1169              Mean of 4.1 years, range 0--9.8        80.4 years, ≥65                                                          Clinical stroke, PD, atypical Parkinsonian syndrome diagnoses, schizophrenia, and other psychotic disorders                                         University of Pennsylvania Smell Identification Test (UPSIT) (40 points score)
  [@B87]       2418              Mean of 12.8 years, maximum 17 years   69 years, 53--97                                                         None                                                                                                                                                San Diego Odor Identification Test (SDOIT) (8 points score)
  [@B24]       1774              10 years                               63.5 years, 40--90                                                       Individuals who met criteria for dementia                                                                                                           Modified version of the Scandinavian Odor-Identification test (SOIT) (13 points score)
  [@B56]       2289              13 years                               75.6 years, 71--82                                                       Difficulty in walking a quarter mile, climbing 10 steps or performing activities of daily living, active cancer treatment in the previous 3 years   Brief Smell Identification Test (BSIT) (12 points score)

PD, Parkinson's disease; OI, olfactory impairment.

###### 

Studies linking olfactory impairment and mortality -- Statistics and results.

  References   Statistical analyses                                                 Covariates                                                                                                                                                                                                     Main results (according to adjustment for covariates)   
  ------------ -------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  [@B96]       Cox proportional hazard models                                       Age, sex, education                                                                                                                                                                                            HR = 0.94 (95%CI: 0.90, 0.98)                           HR predicting mortality for each additional correct answer on the BSIT score.
                                                                                    Boston Naming Test                                                                                                                                                                                             HR = 0.94 (95%CI: 0.90, 0.99)                           
                                                                                    Katz scale, cardiovascular risk factors and conditions                                                                                                                                                         HR = 0.95 (95%CI: 0.90, 0.99)                           
                                                                                    Cognitive, social and physical activity, depressive symptoms                                                                                                                                                   HR = 0.95 (95%CI: 0.91, 0.99)                           
  [@B33]       Cox proportional hazard models -- Multivariate logistic regression   Age, sex                                                                                                                                                                                                       HR = 1.99 (95%CI: 1.42, 2.80)                           HR predicting mortality for moderate OI (SDOIT ≤ 3).
                                                                                    BMI, systolic blood pressure, current smoking status, alcohol consumption, poor self-rated health, visual impairment, hypertension, diabetes, history of cancer, angina, stroke, acute myocardial infarction   HR = 2.04 (95%CI: 1.41, 2.95)                           
                                                                                    Serum total cholesterol                                                                                                                                                                                        HR = 1.68 (95%CI: 1.10, 2.56)                           
                                                                                    Cognitive impairment                                                                                                                                                                                           HR = 1.51 (95%CI: 0.96, 2.38)                           
  [@B75]       Multivariate logistic regression                                     None                                                                                                                                                                                                           OR = 5.85 (95%CI: 3.76, 9.10)                           OR predicting mortality for anosmic subjects (4--5 errors on the Sniffin' Sticks modified score) compared to controls.
                                                                                    Age, sex, education                                                                                                                                                                                            OR = 3.24 (95%CI: 1.99, 5.28)                           
                                                                                    Age, sex, education, comorbidity index                                                                                                                                                                         OR = 3.41 (95%CI: 2.06, 5.64)                           
                                                                                    Age, sex, education, cardiovascular diseases, cancer, lung disease, stroke, diabetes, liver damage                                                                                                             OR = 3.37 (95%CI: 2.04, 5.57)                           
  [@B18]       Cox proportional hazard models -- Multivariate logistic regression   None                                                                                                                                                                                                           HR = 1.068 (95%CI: 1.053, 1.083)                        HR predicting mortality for each additional error on the UPSIT score.
                                                                                    Age, education, race/ethnicity, gender, spanish language, comorbidity index, dementia, depression, head injury, alcohol abuse, BMI, smoking, hearing/vision impairment                                         HR = 1.049 (95%CI: 1.030, 1.068)                        
  [@B87]       Cox proportional hazard models -- Multivariate logistic regression   Age, sex                                                                                                                                                                                                       HR = 1.46 (95%CI: 1.24, 1.73)                           HR predicting mortality for OI (SDOIT ≤ 6).
                                                                                    Age, sex, education, hypertension, diabetes, cardiovascular disease, cancer, cognitive impairment, frailty, smoking, exercise, BMI, alcohol                                                                    HR = 1.29 (95%CI: 1.08, 1.54)                           
                                                                                    Age, sex, education, hypertension, diabetes, cardiovascular disease, cancer, cognitive impairment, frailty, smoking, exercise, BMI, alcohol, IMT, CRP, IL-6                                                    HR = 1.28 (95%CI: 1.07, 1.52)                           
  [@B24]       Cox proportional hazard models -- Multivariate logistic regression   None                                                                                                                                                                                                           HR = 0.74 (95%CI: 0.71, 0.77)                           HR predicting mortality for each additional correct answer on the SOIT.
                                                                                    Age, sex                                                                                                                                                                                                       HR = 0.91 (95%CI: 0.87, 0.95)                           
                                                                                    Years of education                                                                                                                                                                                             HR = 0.91 (95%CI: 0.87, 0.96)                           
                                                                                    Health variables                                                                                                                                                                                               HR = 0.91 (95%CI: 0.87, 0.97)                           
                                                                                    Cognitive performance                                                                                                                                                                                          HR = 0.92 (95%CI: 0.87, 0.97)                           
                                                                                    Dementia conversion                                                                                                                                                                                            HR = 0.92 (95%CI: 0.88, 0.97)                           
                                                                                    Apolipoprotein E ε4                                                                                                                                                                                            HR = 0.92 (95%CI: 0.87, 0.97)                           
  [@B56]       Mediation analyses using risk ratio scale                            Age, sex, race, education, BMI, drinking, brisk walking, smoking, self-reported general health status, cardiovascular disease, cancer, diabetes, hypertension, depressive symptoms, chronic kidney disease     RR = 1.46 (95%CI: 1.27, 1.67)                           RR predicting mortality for OI (BSIT ≤ 8).

HR, hazard ratio; CI, confidence interval; BMI, body mass index; BSIT, Brief Smell Identification Test; OI, olfactory impairment; SDOIT, San Diego Odor Identification Test; OR, odds ratio; UPSIT, University of Pennsylvania Smell Identification Test; IMT, carotid intima plus media thickness; CRP, C-reactive protein; IL-6, interleukin-6; SOIT, Scandinavian Odor-Identification Test; RR, risk ratio.

These studies cannot be directly compared due to methodological differences. However, all yield similar results. Regardless of the statistical method used, the relationship between OI and mortality risk was statistically significant and strong. In addition, the association was found to be dose-dependent, meaning anosmic people have a greater risk of death than hyposmic people.

Unfortunately, while clearly revealing the existence of a link between OI and risk of mortality, these studies leave possible explanations of such a link quite unexplored. Indeed, cause-specific mortality is only explored in one study ([@B56]) whereas others do not report cause of death. Yet, this parameter could have largely contributed to the understanding of the mechanisms of the OI-mortality relationship. Nevertheless, a large number of covariates were controlled, which certainly adds more data to progress through the current hypotheses. Though being a key feature, the causal involvement of neurodegenerative diseases is still left quite unanswered in these studies.

Possible Mechanisms Linking Olfactory Impairment and Risk of Mortality {#S3}
======================================================================

At the moment, the underlying physiopathology linking olfactory impairment to mortality remains unknown. Based on existing evidence and on data from the mortality studies, we will present an overview of current hypotheses.

Effects of Olfactory Loss on Eating Behavior, Danger Warning and Social Interaction {#S3.SS1}
-----------------------------------------------------------------------------------

Olfaction is known to play a role in eating behavior, danger warning and social interaction ([@B91]). OI will therefore have various consequences on these three human functions, which might directly or indirectly lead to decreased health.

First, malnutrition may be a direct consequence of OI as taste and smell are intrinsically linked. In fact, OI may lead to a decreased ability to enjoy food, decreased appetite and food intake, as well as change in body weight and increased risk for chronic disease. People suffering from OI might either maintain their weight, or eat less, or on the contrary eat more since food would become tasteless; reasons for this remain unclear ([@B15]). Interestingly, there is growing evidence that the olfactory system could greatly contribute in the regulation of food intake and energy balance, through its effect on sympathetic and parasympathetic tone ([@B72]; [@B27]; [@B66]). Indeed, receptors to a variety of orexigenic and anorexigenic molecules (i.e., insulin, leptin, ghrelin, neuropeptide Y, nutrient glucose) were found in the olfactory epithelium and in the olfactory bulb ([@B72]; [@B64]). It was shown that older women with OI had poorer diet quality over 5 years ([@B32]) and that a population of older United States female and male adults displayed low body mass index (BMI) ([@B19]). Still, there remain controversies in the literature regarding the association between malnutrition and OI in geriatric patients ([@B35]). Similarly, the relationship between OI and obesity yield contradictory results, some studies demonstrating a correlation (mainly through increased threshold detection of odors ([@B77]; [@B72]), while others did not ([@B34]). Some authors suggest that the wide range of both etiologies and endocrinologic consequences of obesity could explain these conflicting findings ([@B72]). Among our seven reviewed studies, only a few measured BMI of the subjects. One study found that OI was associated with decreased BMI ([@B33]). The other showed that subjects who did not enjoy eating or had a low BMI had increased mortality, whereas those who had a high BMI had decreased mortality ([@B75]). Weight loss, as a surrogate marker for malnutrition, was also found to contribute to the association between OI and mortality ([@B56]). Indeed, their mediation analysis demonstrated that weight loss could account for, respectively, 6 and 11% of the 10-year and 13-year higher mortality linked to poor olfaction.

Olfactory impairment might also increase risk of death as a result of not smelling danger signals in the household environment. A United States survey showed that, respectively, 20.3 and 31.3% of adults older than 70 years were not able to identify the warning odors of smoke and natural gas ([@B40]). OI thus exposes to risks associated with cooking accidents, fires or gas leaks and ingestion of spoiled foods or toxic substances ([@B82]). Anosmic people experience hazardous events 2 to 3 times more often than normosmic subjects ([@B73]). Although the seven studies did not take these events into consideration for analysis of cause-specific mortality, death rate from unintentional poisoning or fire (not necessarily related to OI) is actually low (1.7--4.7 per 100,000) ([@B50]).

Olfactory function is known to influence quality of life. Notably, people with OI typically suffer from depressive symptoms ([@B31]; [@B14], [@B15]; [@B88]). One proposed explanation is that dysfunction or absence of olfactory bulb might result in the dysfunction of various cellular processes and pathways within the hippocampus ([@B65]). Some of the mortality studies reported that the subjects who died showed more depressive signs ([@B96]; [@B24]). However, the association of OI with mortality persisted after controlling for depressive symptoms ([@B96]). OI is associated with reduced social network size ([@B99]), and recent work showed that reduced in-person physical contact with others might partially mediate the link between OI and mortality in females ([@B54]).

Associated Neurodegenerative Diseases {#S3.SS2}
-------------------------------------

At present, OI has become a well-known early biomarker for a broad spectrum of neurodegenerative diseases. Therefore, it is not surprising that neurodegenerative diseases have been investigated as a possible mediator in the relationship between OI and mortality. Despite some conflicting results, evidence is progressively increasing that neurodegenerative diseases might partly explain this relationship.

The majority of the reviewed studies included cognitive function at baseline as a covariate. In three studies, controlling for cognitive performance at baseline did not change the results. Nevertheless, [@B96] excluded patients with a diagnosis of dementia or PD at baseline and used a measure of cognitive activity frequency in leisure time, which seems to weakly reflect cognitive function. [@B87] did not adjust the results exclusively for cognitive function but rather included additional covariates for adjustment, so that the precise impact of cognitive function remains unknown. In addition, [@B24] also specifically addressed the question of dementia conversion and found that the OI-mortality relationship was independent from it. On the contrary, three other studies did show a potential mediator effect of cognitive function on mortality ([@B75]; [@B18]; [@B56]). Two found that the association between OI and mortality was lowered when controlling for dementia, yet remained statistically significant. Of note, OI was shown to be associated with future cognitive decline in cognitively intact subjects ([@B17]). Moreover, there is evidence of existing post-mortem markers of neurodegenerative disease in the brain of subjects without previous clinical signs of MCI or AD ([@B95]). Therefore, one hypothetical explanation for the absence or weak mediating effect of cognitive function on mortality might be that olfaction is altered while clinical cognitive function is not yet affected and thus undiagnosed. Only [@B33] came to a non-significant association between OI and mortality risk after adjustment for cognitive impairment. This would suggest a mediating role of cognitive function, although the authors clearly state this finding could be due to weak statistical power. More interestingly, the only analysis of cause-specific mortality showed that the strongest causal association found was between OI and death associated with dementia or PD ([@B56]). Indeed, their mediation analysis showed that dementia or PD could account for 22% of the higher 10-year mortality linked to poor olfaction. Lastly, [@B18] questions the fact that neurodegenerative disorders lead to excess mortality. However, recent evidence suggests otherwise. In 2014, AD was the sixth leading cause of death in the United States, representing 3.6% of total mortality with an age-adjusted death rate of 25.4 per 100,000 citizens ([@B92]). As for PD, a meta-analysis showed a pooled mortality ratio of approximately 1.5 compared to controls ([@B62]). Also, mean duration until death varies from 6.9 to 14.3 years. This might also partially explain why dementia conversion does not seem to mediate the OI-mortality link despite a 10-year follow-up ([@B24]), since death associated with PD may occur after more than 10 years. PD-related mortality was shown to be significantly increased by the presence of MCI at baseline ([@B41]). This finding supports the idea of a correlation between OI, PD and mortality risk.

Finally, adjusting for ApoE ε4 genotype, associated with cognitive decline and OI ([@B93]), did not attenuate the association between OI and mortality ([@B18]; [@B24]).

In conclusion, even if available data remain controversial, there seems to be growing evidence that neurodegenerative diseases, through cognitive dysfunction, may be a potential mediator in the relationship connecting OI to mortality risk.

Accelerated Brain Aging {#S3.SS3}
-----------------------

One of the special features of the olfactory system is its extraordinary plasticity and continuing neurogenesis through adulthood, at least at the level of the olfactory epithelium (for recent review see [@B44]). Mechanisms underlying these neural abilities have been largely investigated mainly in rodents; indeed, the paucity of human data remains controversial. Adult neurogenesis is thought to occur both peripherally and centrally, in three different locations. First, proliferating stem cells, located within the olfactory epithelium differentiate into olfactory receptor neurons. Secondly, neural stem cells coming from the walls of the lateral ventricle could migrate following the rostral migratory stream toward the olfactory bulb (OB) to give rise to olfactory interneurons ([@B16]). Thirdly, some animal data suggest the presence of progenitor cells lying directly within the OB ([@B44]). For now, however, all this remains somewhat hypothetical in adult human brains. Yet, clinical findings support the idea of high plasticity of the olfactory system. For instance, it is widely acknowledged that the OB is subject to significant volume changes, as a function of olfactory performance. Indeed, OI is associated with reduced OB volume, while recovery of olfactory function correlates with OB volume ([@B78], [@B79]; [@B45]; [@B97]; [@B80]). These volume fluctuations probably depend on bottom-up ([@B67]) and top-down processes ([@B10]). In addition, structural brain modifications could also occur beyond the OB ([@B76]). Finally, olfactory plasticity has also been recently highlighted by olfactory training, which was found to improve significantly olfactory skills regardless of baseline olfactory function ([@B90]) and to lead to increased cortical thickness of certain brain areas ([@B4]). Interestingly, olfactory training was also shown to improve verbal function and subjective well-being in older people ([@B94]).

Importantly, vision and hearing impairment were not associated with mortality nor did they alter the OI-mortality relationship, suggesting that death could not be explained by sensory loss more broadly ([@B18]; [@B87]). Still, some previous studies have shown a possible link between vision and/or hearing impairment and mortality, evidence for the impact of vision impairment alone remaining weaker ([@B25]; [@B87]; [@B55]). It is also important to underline the fact that all humans do not age equally. That is why physiological age might be more relevant than the chronological age. It may be hypothesized that decline in olfactory function could indicate a more advanced physiological age. Indeed, it was found that idiopathic age-related decline in olfactory function was much smaller in the healthy, non-medicated, non-smoking population ([@B61]). On the contrary, it was shown that taste and smell disorders were associated with an increased risk of frailty in the older population ([@B89]; [@B37]). Among the mortality studies, controlling for performance in activities of daily living or frailty score did not attenuate the effect ([@B75]; [@B87]). Global sensory impairment (including the five classical senses: smell, taste, hearing, vision and touch) predicts 5-year mortality, but also major components of physical frailty (e.g., slow gait, weight loss, low activity) ([@B74]). The same authors developed the concept that multisensory loss of function could reflect a common underlying aging process ([@B13]).

To summarize, we hypothesize that OI reflects a decline in brain plasticity, and could be seen more globally as an indicator of lowered physiologic repair function. This could explain, at least partly, the pathway toward increased mortality. Brain aging could make the olfactory system as well as other brain structures more vulnerable and less capable of recovering from insults. This highlights the current need to think in terms of physiological age and frailty status. Whether frailty mediates the relationship between OI and mortality still requires more evidence.

Reflection of General Poor Health {#S3.SS4}
---------------------------------

Olfactory impairment is known to be associated with a wide range of illnesses and is thought to be a marker of poor health. [@B51] showed a negative correlation between olfactory function and the number of comorbid conditions. Self-reported poor health status was associated with OI in one study ([@B56]). However, the association between OI and mortality risk was mostly driven by the subjects with baseline excellent to good health, which might question the idea of OI being merely a marker of poor health. The authors hypothesized either that OI in healthy older people might hide an underneath life-threatening condition or that the cumulative effect of multiple comorbid conditions might outweigh the effect of OI on death. Moreover, half of the analyzed studies adjusted their results for comorbid conditions, with either little or no effect on the OI-mortality link ([@B75]; [@B18]; [@B87]; [@B24]). Controlling for smoking or alcohol abuse did not attenuate the link between OI and mortality ([@B75]; [@B18]). Some authors also suggested that high levels of inflammatory markers (interleukin-6, C-reactive protein) could be associated with frailty, atherosclerosis and also with OI ([@B86]; [@B39]; [@B53]). However, adjusting for these variables did not attenuate the link between OI and mortality ([@B87]). Hence, whether OI is a marker of poor health remains doubtful. The only assertion that can be made is that OI is a strong and independent risk factor for death, regardless of health status.

Since controlling for comorbid conditions had little or no effect on the OI-mortality link, this would then suggest a weak impact of cardiovascular diseases or metabolic disorders (being part of the comorbidity indexes used in the studies).

However, analysis of cause-specific mortality revealed that OI was modestly associated with death from cardiovascular disease, but not from cancer or respiratory diseases ([@B56]). Furthermore, the association between OI and mortality did not remain significant after adjusting for total serum cholesterol, though potentially explained by reduced statistical power ([@B33]). Physical exercise and use of statins were found to decrease the incidence of OI ([@B86]). Indeed, both are known to improve cardiovascular health and to lower the risk of atherosclerosis, which is the main hallmark of cardiovascular diseases. Additionally, statins may also directly provide to the brain (and thereby to the olfactory system) their positive pleiotropic effects on endothelial function, oxidative stress and vascular inflammation. This would be consistent with the reduced risk of OI being specific to statins crossing well the blood-brain barrier in the study from [@B86]. However, in a mouse model, administration of atorvastatin (classified as not crossing the blood-brain barrier) could still enhance the recovery of olfactory function, likely through the promotion of cellular proliferation and neural regeneration of the olfactory epithelium ([@B48], [@B49]). Carotid artery intima media thickness (IMT), a biomarker of generalized atherosclerosis, was shown to be associated with a decline in odor identification performance at 5 years, but only before 60 years old ([@B84], [@B85]). Nevertheless, the association between OI and mortality remained statistically significant after adjusting for IMT ([@B87]). Also, OI could be associated to the intake of antihypertensive drugs ([@B21]). Therefore, cardiovascular diseases might be somehow connected to OI. Yet, evidence remains sparse and further studies are needed.

Obesity, insulin resistance and type 2 diabetes mellitus constitute a well-known continuum which represents a major burden in terms of public health and mortality. In rodent obesity models, the olfactory bulb developed insulin resistance which could then be responsible for the disruption of olfactory function ([@B72]). Human data also support the fact that insulin resistance could affect negatively olfactory function. Indeed, a recent study found that older adults with high insulin resistance (quantified by the HOMA-IR test) had an approximately 2-fold increased odds of OI compared with subjects with low insulin resistance ([@B64]). This could explain, at least in part, the independent association found between type 2 diabetes mellitus (in which insulin resistance represents the key mechanism) and OI ([@B33]; [@B34]; [@B98]). OI in type 2 diabetes mellitus might also be due to microvascular injury since OI was mainly found in diabetic patients already suffering from the microvascular complications of this disease ([@B34]). Regarding mortality studies, diabetes mellitus was associated with OI in one study ([@B33]) but was not in another one more recent ([@B56]). Three studies included diabetes mellitus in their controlled variables, but the correlation between OI and mortality remained unchanged, thus also suggesting a weak impact of diabetes mellitus. Regarding the link of obesity, insulin resistance and type 2 diabetes mellitus with OI, controversies thus persist on many points.

Finally, due to its direct contact to the outside, the olfactory system may be an easy target for environmental insults. Indeed, olfaction is altered by air pollutants and by exposure to a variety of toxic agents (e.g., metallic compounds) ([@B2], [@B3]; [@B29]). The airborne toxicants may also make their way to the brain directly through the olfactory pathway, leading to neuronal damage. Of note, it was shown that high levels of air pollution could result in neurodegenerative diseases-related pathology within the olfactory bulb ([@B9]). Pollution and toxic exposure have been linked to poor health and might thus constitute a potential mediator in the relationship between OI and mortality ([@B26]).

Conclusion {#S4}
==========

Studies agree that OI is an indicator of increased mortality risk in the older population. Several hypothetical mechanisms are suggested, yet the extent to which they contribute to this association remains an open question. To our opinion, the effects of olfactory impairment on eating behavior, danger warning and social interaction do exist, although their importance in this context seems minor. Olfactory impairment and poor health status seem to be linked in some ways, though the exact relationship remains poorly understood. On the contrary, based on current evidence, neurodegenerative diseases and advanced physiological brain aging appear to us as the most likely involved. The olfactory system plays a determinant role and further attention should be given to these potential mechanisms underlying the robust OI-mortality association. In the future, we should also address the question whether the recovery of olfactory function could have beneficial effects on outcome.
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